Patents by Inventor Punit Bhardwaj
Punit Bhardwaj has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20120269769Abstract: Compounds of formula (I): wherein B, X, R3, L0, L1, L2, R2, R1 and RC are defined herein. The compounds are useful as inhibitors of HCV NS3 protease for the treatment of hepatitis C viral infection.Type: ApplicationFiled: July 3, 2012Publication date: October 25, 2012Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Montse LLINAS-BRUNET, Murray BAILEY, Punit BHARDWAJ, Josee BORDELEAU, Pasquale FORGIONE, Elise GHIRO, Vida GORYS, Nathalie GOUDREAU, Sylvie GOULET, Teddy HALMOS, Jean RANCOURT
-
Publication number: 20120034187Abstract: Compounds of formula (I): wherein B, X, R3, L0, L1, L2, R2, R1 and RC are defined herein. The compounds are useful as inhibitors of HCV NS3 protease for the treatment of hepatitis C viral infection.Type: ApplicationFiled: October 21, 2011Publication date: February 9, 2012Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Montse LLINAS-BRUNET, Murray BAILEY, Punit BHARDWAJ, Josee BORDELEAU, Pasquale FORGIONE, Elise GHIRO, Vida GORYS, Nathalie GOUDREAU, Sylvie GOULET, Teddy HALMOS, Jean RANCOURT
-
Publication number: 20110177030Abstract: Compounds of formula (I): wherein B, X, R3, L0, L1, L2, R2, R1 and RC are defined herein. The compounds are useful as inhibitors of HCV NS3 protease for the treatment of hepatitis C viral infection.Type: ApplicationFiled: April 1, 2011Publication date: July 21, 2011Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Montse LLINAS-BRUNET, Murray BAILEY, Punit BHARDWAJ, Josee BORDELEAU, Pasquale FORGIONE, Elise GHIRO, Vida GORYS, Nathalie GOUDREAU, Sylvie GOULET, Teddy HALMOS, Jean RANCOURT
-
Patent number: 7939667Abstract: Compounds of formula (I): wherein B, X, R3, L0, L1, L2, R2, R1 and RC are defined herein. The compounds are useful as inhibitors of HCV NS3 protease for the treatment of hepatitis C viral infection.Type: GrantFiled: June 21, 2007Date of Patent: May 10, 2011Assignee: Boehringer Ingelheim International GmbHInventors: Montse Llinas-Brunet, Murray Bailey, Punit Bhardwaj, Josee Bordeleau, Pasquale Forgione, Elise Ghiro, Vida Gorys, Nathalie Goudreau, Sylvie Goulet, Teddy Halmos, Jean Rancourt
-
Patent number: 7705146Abstract: The invention relates to compounds of formula (I) wherein R?, R2, R3, R4, R5, R6, Y, n and m are as defined herein. The compounds are useful for the treatment and prevention of hepatitis C viral infections in mammals by inhibiting HCV NS3 protease. The invention further relates to azalactone compounds of the formula (III) which can be reacted with an amide anion to produce the compounds of formula (I).Type: GrantFiled: June 22, 2005Date of Patent: April 27, 2010Assignee: Boehringer Ingelheim International GmbHInventors: Murray D. Bailey, Punit Bhardwaj, Pasquale Forgione, Elise Ghiro, Nathalie Goudreau, Teddy Halmos, Montse Llinas-Brunet, Marc-Andre Poupart, Jean Rancourt
-
Patent number: 7696242Abstract: Compounds of formula (I): wherein R1, R2, R3, R4, R5, Y, n and m are as defined herein. The compounds are useful as inhibitors of HCV NS3 protease.Type: GrantFiled: July 19, 2005Date of Patent: April 13, 2010Assignee: Boehringer Ingelheim International GmbHInventors: Murray D. Bailey, Punit Bhardwaj, Elise Ghiro, Nathalie Goudreau, Teddy Halmos, Montse Llinas-Brunet, Marc-André Poupart, Jean Rancourt
-
Publication number: 20100028300Abstract: Compounds of formula I: wherein D, R4, R3, L0, L1, L2, R2 and RC are defined herein; or a pharmaceutically acceptable salt thereof, useful as inhibitors of the HCV NS3 protease.Type: ApplicationFiled: September 28, 2009Publication date: February 4, 2010Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Montse LLINAS-BRUNET, Murray BAILEY, Punit BHARDWAJ, Pasquale FORGIONE, Elise GHIRO, Nathalie GOUDREAU, Teddy HALMOS, Jean RANCOURT
-
Patent number: 7642235Abstract: Compounds of formula I: wherein D, R4, R3, L0, L1, L2, R2 and RC are defined herein; or a pharmaceutically acceptable salt thereof, useful as inhibitors of the HCV NS3 protease.Type: GrantFiled: September 20, 2004Date of Patent: January 5, 2010Assignee: Boehringer Ingelheim International GmbHInventors: Montse Llinas-Brunet, Murray Bailey, Punit Bhardwaj, Elise Ghiro, Nathalie Goudreau, Teddy Halmos
-
Patent number: 7585845Abstract: Compounds of formula (I): wherein B, X, R3, L0, L1, L2, R2, R1 and RC are defined herein. The compounds are useful as inhibitors of HCV NS3 protease for the treatment of hepatitis C viral infection.Type: GrantFiled: May 20, 2004Date of Patent: September 8, 2009Assignee: Boehringer Ingelheim International GmbHInventors: Montse Llinas-Brunet, Murray Bailey, Punit Bhardwaj, Josee Bordeleau, Pasquale Forgione, Elise Ghiro, Vida Gorys, Nathalie Goudreau, Sylvie Goulet, Teddy Halmos, Jean Rancourt
-
Publication number: 20090156822Abstract: Compounds of formula (I): wherein R1, R2, R3, R4, n and m are as defined herein. The compounds are useful as inhibitors of HCV NS3 protease.Type: ApplicationFiled: February 10, 2009Publication date: June 18, 2009Applicant: Boehringer Ingelheim International GmbHInventors: Murray D. BAILEY, Punit BHARDWAJ, Elise GHIRO, Nathalie GOUDREAU, Teddy HALMOS, Montse LLINAS-BRUNET, Marc-Andre POUPART, Jean RANCOURT
-
Patent number: 7511157Abstract: Compounds of formula (I): wherein R1, R2, R3, R4, n and m are as defined herein. The compounds are useful as inhibitors of HCV NS3 protease.Type: GrantFiled: July 19, 2005Date of Patent: March 31, 2009Assignee: Boehringer Ingelheim International GmbHInventors: Murray D. Bailey, Punit Bhardwaj, Elise Ghiro, Nathalie Goudreau, Teddy Halmos, Montse Llinas-Brunet, Marc-André Poupart, Jean Rancourt
-
Publication number: 20070243166Abstract: Compounds of formula (I): wherein B, X, R3, L0, L1, L2, R2, R1 and RC are defined herein. The compounds are useful as inhibitors of HCV NS3 protease for the treatment of hepatitis C viral infection.Type: ApplicationFiled: June 21, 2007Publication date: October 18, 2007Inventors: Montse LLINAS-BRUNET, Murray BAILEY, Punit BHARDWAJ, Josee BORDELEAU, Pasquale FORGIONE, Elise GHIRO, Vida GORYS, Nathalie GOUDREAU, Sylvie GOULET, Teddy HALMOS, Jean RANCOURT
-
Publication number: 20060258868Abstract: The invention relates to compounds of formula (I) wherein R?, R2, R3, R4, R5, R6, Y, n and m are as defined (herein. The compounds are useful for the treatment and prevention of hepatitis C viral infections in mammals by inhibiting HCV NS3 protease. The invention further relates to azalactone compounds of the formula (III) which can be reacted with an amide anion to produce the compounds of formula (I).Type: ApplicationFiled: June 22, 2005Publication date: November 16, 2006Applicant: Boehringer Ingelheim International GmbHInventors: Murray Bailey, Punit Bhardwaj, Pasquale Forgione, Elise Ghiro, Nathalie Goudreau, Teddy Halmos, Montse Llinas-Brunet, Marc-Andre Poupart, Jean Rancourt
-
Publication number: 20060046965Abstract: Compounds of formula (I): wherein R1, R2, R3, R4, n and m are as defined herein. The compounds are useful as inhibitors of HCV NS3 protease.Type: ApplicationFiled: July 19, 2005Publication date: March 2, 2006Applicant: Boehringer Ingelheim International GmbHInventors: Murray Bailey, Punit Bhardwaj, Elise Ghiro, Nathalie Goudreau, Teddy Halmos, Montse Llinas-Brunet, Marc-Andre Poupart, Jean Rancourt
-
Publication number: 20060019905Abstract: Compounds of formula (I): wherein R1, R2, R3, R4, R5, Y, n and m are as defined herein. The compounds are useful as inhibitors of HCV NS3 protease.Type: ApplicationFiled: July 19, 2005Publication date: January 26, 2006Applicant: Boehringer Ingelheim International GmbHInventors: Murray Bailey, Punit Bhardwaj, Elise Ghiro, Nathalie Goudreau, Teddy Halmos, Montse Llinas-Brunet, Marc-Andre Poupart, Jean Rancourt
-
Publication number: 20050192212Abstract: Compounds of formula (I): wherein R1, R2, X, R3, D, and the dotted line b are as defined herein; or a pharmaceutically acceptable salt or ester thereof, are useful as inhibitors of the HCV NS3 protease.Type: ApplicationFiled: January 19, 2005Publication date: September 1, 2005Applicant: Boehringer Ingelheim International GmbHInventors: Montse Llinas-Brunet, Murray Bailey, Punit Bhardwaj, Francois Bilodeau, Pasquale Forgione, Elise Ghiro, Nathalie Goudreau, Teddy Halmos, Jean Rancourt
-
Publication number: 20050080005Abstract: Compounds of formula I: wherein D, R4, R3, L0, L1, L2, R2 and Rc are defined herein; or a pharmaceutically acceptable salt thereof, useful as inhibitors of the HCV NS3 protease.Type: ApplicationFiled: September 20, 2004Publication date: April 14, 2005Applicant: Boehringer Ingelheim International GmbHInventors: Montse Llinas-Brunet, Murray Bailey, Punit Bhardwaj, Pasquale Forgione, Elise Ghiro, Nathalie Goudreau, Teddy Halmos, Jean Rancourt
-
Publication number: 20050020503Abstract: Compounds of formula (I): wherein B, X, R3, L0, L1, L2, R2, R1 and RC are defined herein. The compounds are useful as inhibitors of HCV NS3 protease for the treatment of hepatitis C viral infection.Type: ApplicationFiled: May 20, 2004Publication date: January 27, 2005Applicant: Boehringer Ingelheim International GmbHInventors: Montse Llinas-Brunet, Murray Bailey, Punit Bhardwaj, Josee Bordeleau, Pasquale Forgione, Elise Ghiro, Vida Gorys, Nathalie Goudreau, Sylvie Goulet, Teddy Halmos, Jean Rancourt
